Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 15/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18543722 | 0.88 | P2RX4 (0.52) | P2RX4MAPTMEN1KMT2A | |
| SCHEMBL14972561 | 0.88 | P2RX4 (0.55) | P2RX4MAPTMEN1KMT2A | |
| SCHEMBL14972509 | 0.88 | P2RX4 (0.55) | P2RX4MAPTMEN1KMT2A | |
| SCHEMBL14972529 | 0.86 | P2RX4 (0.50) | P2RX4MAPTMEN1KMT2A | |
| SCHEMBL14972867 | 0.86 | P2RX4 (0.50) | P2RX4MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL14972545 | 0.85 | P2RX4 (0.49) | P2RX4MAPTMEN1KMT2A | |
| SCHEMBL14972537 | 0.84 | P2RX4 (0.54) | P2RX4MAPTMEN1KMT2A | |
| SCHEMBL14972590 | 0.84 | P2RX4 (0.59) | P2RX4HPGDMAPTMEN1KMT2A | |
| SCHEMBL16239044 | 0.84 | P2RX4 (0.55) | P2RX4 | |
| SCHEMBL14972502 | 0.84 | P2RX4 (0.57) | P2RX4MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023157895-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR ENDOMETRIOSIS OR ADENOMYOSIS | 国立大学法人 鳥取大学 | 2023-08-24 | — | — | WO | disclosed |
| US-20230248738-A1 | MEDICAMENT FOR TREATING COUGH | NIPPON CHEMIPHAR CO., LTD (JP) | 2023-08-10 | — | — | US | disclosed |
| EP-4190356-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOMS ASSOCIATED WITH ALLERGIC REACTION | Nippon Chemiphar Co., Ltd. (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-11666582-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20230149421-A1 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4129296-A1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Università di Pisa (IT) | 2023-02-08 | — | — | EP | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| WO-2021198745-A1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | アントニオーリ ルーカ | 2021-10-07 | — | — | WO | disclosed |
| US-20210205326-A1 | MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3766497-A1 | DRUG FOR TREATING COUGH | Nippon Chemiphar Co., Ltd. (JP) | 2021-01-20 | — | — | EP | disclosed |
| US-20210000840-A1 | MEDICAMENT FOR TREATING COUGH | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-01-07 | — | — | US | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| US-10633349-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-07-19 | — | — | US | disclosed |
| US-9969700-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | TRPM4, TRPM7, P2RX3 | P2RX4 5/4885HPGD 712/4885MAPT 1093/4885 |
| US-20210205326-A1 | MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY | P2RX4, P2RX3, P2RX1 | P2RX4 1/4885HPGD 1577/4885MAPT 87/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885HPGD 1251/4885MAPT 4724/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885HPGD 1251/4885MAPT 4724/4885 |
| US-20210000840-A1 | MEDICAMENT FOR TREATING COUGH | P2RX4, P2RX3, P2RX5 | P2RX4 1/4885HPGD 1051/4885MAPT 366/4885 |
| US-10633349-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885HPGD 1251/4885MAPT 4724/4885 |
| US-11666582-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | P2RX4 1/4885HPGD 1051/4885MAPT 366/4885 |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885HPGD 1251/4885MAPT 4724/4885 |
| US-20230149421-A1 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | P2RX5, P2RX3, P2RX2 | P2RX4 5/4885HPGD 1382/4885MAPT 4023/4885 |
| US-20230248738-A1 | MEDICAMENT FOR TREATING COUGH | P2RX4, P2RX3, P2RX5 | P2RX4 1/4885HPGD 1051/4885MAPT 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.